Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||AMG 511 + Sotorasib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AMG 511||AMG-511|AMG511||PI3K Inhibitor (Pan) 40||AMG 511 selectively inhibits class I PI3K, which may leads to inhibition of tumor cell growth (PMID: 22897589).|
|Sotorasib||Lumakras||AMG 510|AMG510|AMG-510||KRAS G12C inhibitor 32||Lumakras (sotorasib) is small molecule inhibitor that selectively targets KRAS G12C and inhibits downstream signaling, which may lead to growth inhibition of tumors harboring KRAS G12C (PMID: 31666701). Lumakras (sotorasib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|